Y-mAbs Therapeutics (YMAB) Revenue & Revenue Breakdown
Y-mAbs Therapeutics Revenue Highlights
Latest Revenue (Y)
$84.82M
Latest Revenue (Q)
$22.80M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Y-mAbs Therapeutics Revenue by Period
Y-mAbs Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $84.82M | 29.96% |
| 2022-12-31 | $65.27M | 87.03% |
| 2021-12-31 | $34.90M | 68.18% |
| 2020-12-31 | $20.75M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Y-mAbs Therapeutics generated $84.82M in revenue during NA 2023, up 29.96% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Y-mAbs Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $22.80M | 14.38% |
| 2024-03-31 | $19.93M | -14.69% |
| 2023-12-31 | $23.36M | 14.22% |
| 2023-09-30 | $20.45M | -1.43% |
| 2023-06-30 | $20.75M | 2.47% |
| 2023-03-31 | $20.25M | -35.60% |
| 2022-12-31 | $31.45M | 150.83% |
| 2022-09-30 | $12.54M | 16.12% |
| 2022-06-30 | $10.80M | 2.97% |
| 2022-03-31 | $10.49M | 9.25% |
| 2021-12-31 | $9.60M | 7.06% |
| 2021-09-30 | $8.96M | -18.14% |
| 2021-06-30 | $10.95M | 103.44% |
| 2021-03-31 | $5.38M | -74.06% |
| 2020-12-31 | $20.75M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Y-mAbs Therapeutics generated $22.80M in revenue during Q2 2024, up 14.38% compared to the previous quarter, and up 112.58% compared to the same period a year ago.
Y-mAbs Therapeutics Revenue Breakdown
Y-mAbs Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| License | $500.00K | $16.00M | $2.00M |
| Product | $84.32M | $49.27M | $32.90M |
Y-mAbs Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (99.41%), and License (0.59%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $500.00K | $15.00M | - | $1.00M | - | - | $2.00M | - | - | - | - |
| Product | $19.43M | $63.57M | $20.75M | $16.45M | $12.54M | $9.80M | $9.60M | $8.96M | $8.95M | $5.38M | - |
| Product, DANYELZA | - | - | $2.52M | $10.49M | - | - | - | - | - | - | - |
Y-mAbs Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (97.49%), and License (2.51%).
Y-mAbs Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| UNITED STATES | $67.81M | - |
| Non-US | $16.50M | - |
| Other countries | - | $3.01M |
| United States | - | $46.26M |
Y-mAbs Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (80.43%), and Non-US (19.57%).
Quarterly Revenue by Country
| Country | Mar 24 | Jun 23 | Mar 23 |
|---|---|---|---|
| Non-US | $821.00K | - | - |
| UNITED STATES | $18.61M | - | - |
| Europe | - | - | $2.52M |
| CHINA | - | $3.54M | - |
| United States | - | $15.85M | $16.83M |
| Other countries | - | $4.90M | $3.42M |
Y-mAbs Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (95.77%), and Non-US (4.23%).
Y-mAbs Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MIRM | Mirum Pharmaceuticals | $186.37M | $69.22M |
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| YMAB | Y-mAbs Therapeutics | $84.82M | $22.80M |
| ARQT | Arcutis Biotherapeutics | $59.61M | $30.86M |
| MRUS | Merus | $43.95M | $11.77M |
| MRSN | Mersana Therapeutics | $36.85M | $2.29M |
| VECT | VectivBio | $27.34M | $676.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| BLUE | bluebird bio | $3.60M | $16.10M |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| LRMR | Larimar Therapeutics | - | - |
| ZNTL | Zentalis Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |
YMAB Revenue FAQ
What is Y-mAbs Therapeutics’s yearly revenue?
Y-mAbs Therapeutics's yearly revenue for 2023 was $84.82M, representing an increase of 29.96% compared to 2022. The company's yearly revenue for 2022 was $65.27M, representing an increase of 87.03% compared to 2021. YMAB's yearly revenue for 2021 was $34.9M, representing an increase of 68.18% compared to 2020.
What is Y-mAbs Therapeutics’s quarterly revenue?
Y-mAbs Therapeutics's quarterly revenue for Q2 2024 was $22.8M, a 14.38% increase from the previous quarter (Q1 2024), and a 9.86% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $19.93M, a -14.69% decrease from the previous quarter (Q4 2023), and a -1.58% decrease year-over-year (Q1 2023). YMAB's quarterly revenue for Q4 2023 was $23.36M, a 14.22% increase from the previous quarter (Q3 2023), and a -25.71% decrease year-over-year (Q4 2022).
What is Y-mAbs Therapeutics’s revenue growth rate?
Y-mAbs Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 143.06%, and for the last 5 years (2019-2023) was 0%.
What are Y-mAbs Therapeutics’s revenue streams?
Y-mAbs Therapeutics's revenue streams in c 23 are License, and Product. License generated $500K in revenue, accounting 0.59% of the company's total revenue, down -96.88% year-over-year. Product generated $84.32M in revenue, accounting 99.41% of the company's total revenue, up 71.15% year-over-year.
What is Y-mAbs Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Y-mAbs Therapeutics was Product. This segment made a revenue of $84.32M, representing 99.41% of the company's total revenue.